News
John King, a candidate for U.S. Senate, said Georgia Sens. Jon Ossoff and Raphael Warnock didn't respond to calls to help Afghans, but emails tell a more nuanced story.
Cold Fusion on MSN2d
Tesla Model S Goes 752 Miles on a Single Charge with Gemini BatteryA Tesla Model S equipped with Our Next Energy’s (ONE) revolutionary Gemini battery has just driven 752 miles on a single charge in a real-world test. This marks a new milestone in electric vehicle ...
Even before a single dancer took the McCaw Hall stage, the audience was primed for the opening night Friday of Pacific ...
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who ...
Shares of PDD Holdings Inc. PDD fell sharply in today's pre-market trading following weaker-than-expected first-quarter ...
Dystrophic epidermolysis bullosa (DEB) is one of the main subtypes of epidermolysis bullosa, a group of genetic skin ...
In a deep dive into the evolving landscape of soca and calypso, The UWI’s Department of Literary, Cultural and Communication ...
Detailed price information for Abeona Therapeutics (ABEO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Abeona Therapeutics (ABEO-Q) from The Globe and Mail including charting and trades.
Abeona Therapeutics Inc.'s ABEO stock traded higher on Wednesday. The Food and Drug Administration (FDA) on Tuesday approved Abeona’s Zevaskyn (prademagene zamikeracel) gene-modified cellular ...
Hosted on MSN1mon
ABEO: Zevaskyn™ Approved by FDA; Raising Valuation to $11…On April 29, 2025, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in ...
Abeona Therapeutics Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing gene and cell therapies, has seen its stock price surge to a 52-week high, touching $6.83.According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results